Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

OBJECTIVE: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients. DESIGN: Phase IIb, single-arm, open-label, multicenter study. METHODS: One hundred and twelve antiretroviral-naive, HIV-1-infected patients received DRV/r 800/100 mg once da...

Full description

Saved in:
Bibliographic Details
Main Authors: Taiwo, Babafemi, Zheng, Lu, Gallien, Sebastien, Matining, Roy M., Kuritzkes, Daniel R., Wilson, Cara C., Berzins, Baiba I., Acosta, Edward P., Bastow, Barbara, Kim, Peter S., Eron, Joseph J.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3515052/
https://ncbi.nlm.nih.gov/pubmed/21857490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0b013e32834bbaa9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items